Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Nicolas Floc’h, Darren A.E. Cross, Jonathan W. Riess et al.|Molecular Cancer Therapeutics|2018

Cited by 113